Recent publications reported associations between loss of GPR151 function and low body mass index (BMI), raising the possibility of inhibiting GPR151 for the treatment of obesity and metabolic syndromes. Here, GPR151 is linked to obesity due to melanocortin 4 receptor deficiency.